Clonazepam Dosing for Panic Disorder
For adults with panic disorder, start clonazepam at 0.25 mg twice daily, then increase to a target dose of 1 mg/day after 3 days, which is the optimal dose for most patients. 1
Initial Dosing Strategy
The FDA-approved dosing schedule is straightforward:
- Starting dose: 0.25 mg twice daily (0.5 mg/day total)
- Target dose: Increase to 1 mg/day after 3 days
- Maximum dose: 4 mg/day if needed, though rarely necessary 1
This recommendation is based on a large fixed-dose study (413 patients) demonstrating that 1 mg/day provided optimal efficacy with the best balance of therapeutic benefit and tolerability 2. Higher doses (2-4 mg/day) were not more effective and caused significantly more adverse effects, particularly somnolence and ataxia 2.
Dose Titration Beyond 1 mg/day
If 1 mg/day proves insufficient after adequate trial:
- Increase in increments of 0.125-0.25 mg twice daily every 3 days
- Most patients respond to 1-2 mg/day 2, 3
- Doses above 2 mg/day rarely provide additional benefit and substantially increase side effects
- The mean effective dose in flexible-dose studies was 2.3 mg/day 1
At endpoint with 1 mg/day, 74% of patients were panic-attack free compared to 56% on placebo 1, representing a clinically meaningful difference with a number needed to treat of 4 4.
Administration Timing
- Divide total daily dose into two administrations (morning and evening) 1
- Consider giving the full dose at bedtime to minimize daytime somnolence, particularly if sedation is problematic 1
- Peak plasma concentrations occur 1-4 hours after oral administration with 90% bioavailability 5
Duration of Treatment and Discontinuation
Continue treatment for at least 6-12 months after achieving remission before considering discontinuation. The evidence shows:
- Clonazepam can be safely discontinued with gradual tapering 6, 3
- Taper by 0.25 mg per week when reducing from doses ≤1 mg/day 6
- For doses >1 mg/day, decrease by 0.5 mg every 2 weeks until reaching 1 mg/day, then switch to 0.25 mg weekly decrements 6
- Decrease by 0.125 mg twice daily every 3 days is the FDA-recommended schedule 1
In a study of 73 patients on clonazepam for ≥3 years (mean dose 2.7 mg/day), 68.9% successfully discontinued using this gradual taper protocol, with withdrawal symptoms being mostly mild (anxiety, tremor, nausea, insomnia) 6.
Critical Cautions and Contraindications
Do not use or use with extreme caution in patients with:
- Significant liver disease (clonazepam undergoes extensive hepatic metabolism) 1, 5
- Respiratory depression or sleep apnea (doses of 0.5-1 mg can worsen sleep-disordered breathing) 5
- Elderly patients (start at lower doses due to increased risk of falls, confusion, and cognitive impairment) 7
- Neurodegenerative disorders (increased sensitivity to sedation and cognitive effects) 7
The half-life of 30-40 hours means steady-state is reached in approximately 5-7 days, and morning sedation is common due to drug accumulation 5.
Common Adverse Effects
The most frequent side effects include:
- Somnolence (most common, particularly problematic in morning) 5, 2
- Ataxia and coordination problems (dose-related, more common at ≥3 mg/day) 2
- Depression, dizziness, fatigue 2
- Memory dysfunction 5
Importantly, clonazepam does not induce its own metabolism and shows minimal tolerance development 1, though physical dependence will develop with regular use requiring gradual discontinuation.
Efficacy Evidence
Multiple high-quality trials demonstrate clonazepam's efficacy:
- Response rates: 62-74% vs. 37-56% for placebo 1, 3
- Reduction of approximately 1 panic attack per week compared to placebo 1
- Rapid onset of action (within 1-2 weeks) 8
- Low-quality evidence suggests possible superiority over placebo, though long-term data are limited 4
Women may require higher doses than men (mean 1.4 mg vs. 0.68 mg) to achieve symptom control 5, though this finding requires confirmation.